The 3rd International Biopharmaceutical Industry Development Innovation Forum

The 3rd International Biopharmaceutical Industry Development Innovation Forum
Topic:International pharmaceutical innovation---Innovative drug R&D and human health

Place: Renaissance Shanghai Pudong Hotel （ Five-Star ）
Date: Apr. 22 nd - 23 rd , 2010 （ Thursday -Friday ）

Organizers ：SEBMC

INVITATION

The 3rd International Biopharmaceutical Industry Development Innovation Forum, organized by Sino-EU Chemical Manufacturers Association Biomedical Committee （ SEBMC ） will be held on Apr.22 nd -23 rd ,2010 at Renaissance Shanghai Pudong Hotel. At that time, more than 200 representatives and experts from the USA, Europe, China, Asia-pacific and international leading drug and medical specialists wiil attend. This forum will focus on global Innovative bio-pharmaceutical R & D innovation and human health, the antibody-based drugs, new vaccines, genetic engineering drugs, antibody humanization technology, new drug development technology, recombinant human protein, gene therapy, cell therapy and interferon and the development and application of medical innovation, anti - infection drugs, antineoplastic agents, anti-diabetic drugs and the cardiovascular system drugs, nervous system drugs, anti-drug discovery and treatment of major diseases, drug discovery, drug design, drug clinical trials, patents and licensing, innovation and outsourcing of drug and clinical trials Asia’s opportunity for healthy development of bio-pharmaceutical industry environment . Forum will also explore a unique set of drug R & D innovation and drug R & D cooperation in the new model, to break through modern biotechnology and bring innovative solutions to the biomedical industry chain. We sincerely would like to invite you to attend this forum and share the field of pharmaceutical R&D and clinical innovation and application, and cooperation in the future.

Sino-EU Chemical Manufacturers Association Biomedical Committee

Agenda

On Apr.21 st ,2010 ( Wednesday ) Check in for foreign representatives

On the morning of Apr. 22nd,2010(Thursday) u Seminar: International Biopharmaceutical R&D Innovation Summit
Executive Chairman: Yetunde Taiwo, Ph.D, Director of Global R&D, Eli Lilly

8:15-8:50AM Check in/ Wearing badges to attend

8:00AM Innovation show open to the public all day

9:00AM Opening Ceremony : Chairman’s oration

9:10AM Keynote Speeches .

Topic: International Biopharmaceutical R&D Innovation and Human Health.

Main topics:
•  The global pharmaceutical R & D innovation and development of hot spot treatment
•  Drug discovery, new drugs design, Clinical trials of new drugs, Safety Assessment, Drug Patents and licensing
•  Fully human monoclonal antibody drug technology and vaccine technologies, biochip technology, Stem cells and small molecule RNA interference, Drug target discovery and drug innovation.
•  New drugs R & D outsourcing and clinical technology service
•  New contagion vaccine invention and diagnosis.
•  Anti- major disease drug development technology
•  China ’s new drug reform and drugs R&D innovative opportunity
•  Transforming medicine and treatment of neurodegenerative disease
•  Anti-tumor monoclonal antibody drug discovery and clinical diagnosis
•  Anti-tumor McAb innovation R&D and clinical diagnosis
•  Technological innovation for antibody Humanization
•  H1N1 flu vaccine development , precaution, control, diagnosis and treatment

10:50 AM Tea break / Communication

11:10AM Symposium: How will Chinese drugs R&D successfully integrate into the international innovation and development of new drug development chain optimization?

Panelists:
Alex Fowkes Ph.D, President of Pfizer Pharmaceuticals Limited, Asia-pacific
Lee E. Babiss Ph.D, global R&D director of Roche
Yetunde Taiwo, Ph.D, Director of Global R&D, Eli Lilly
Thomas G. Evans Ph.D, Vice-president of Novartis China
Zhen Wu, Deputy Secretary of State Food and Drug Administration of the People’s Republic of China
Mingde Yu, President of China Pharmaceutical Enterprise Management Association
Brian Toohey, Senior Vice-president of PhRMA
Hong zheng, Director of Drug Administration Division, China Ministry of Health,

12: 1 0AM Innovation Declaration Signing Ceremony (Innovation of bio-technology creats human health)

12:20AM Joint photos

12:30AM Buffet lunch
On the afternoon of April. 22nd,2010(Thursday) New drugs R&D and CRO cooperation International Conference

Executive Chairman: Prof. Olaf Doessel, Chairman of German Bio-Medical Technology Association

13:30PM Presentation
Topic: Innovative drug discovery and clinical trials outsourcing opportunities in Asia

15:10 PM Tea break/ communications

16:25PM Panel discussion
Topic: China ’s new health care reform policy implementation, the new opportunities and challenges of drug discovery services?

China ’s new health care reformed policy implementation, the new opportunities and challenges of drug discovery services? How to develop the new model of innovative drug R&D outsourcing and clinical technology? What is the new way of Chinese innovative drugs R&D outsourcing and clinical technology? How will the pharmaceutical manufacturers and CRO get into the win-win cooperation?

Panelists:
Jingsong Wang Ph.D, Director of Squibb drug discovery and clinical pharmacokinetics
Garry Neil, Ph.D, Group Vice President of Johnson & Johnson
Mr. Ge Lee, Director of board and CEO of WuXi AppTec Co., Ltd.
Mr. Jisong Cui, Chairman of SAPA
Perry Nisen, Ph.D, Senior Vice President of GSK
Nahed Ahmed ， Ph.D, R&D Vice President of Amgen
Mr. Yu Peng, Chairman of China Bio-Medical Technology Association
Johan Weigelt ， Ph.D, Deputy Director of Structural genomics Research Alliance, Karolinska Institute Stockholm Sweden
Manni KantipudiPh.D, Pesident of GVK, India

18:00PM Welcome Banquet

On the morning of Apr. 23rd,2010 (Friday) u Seminar: Innovative anti-body drugs R&D and clinical international conference
Executive Chairman: Neil W.Gibson. PhD, Chief Scientific Officer of tumor research, Pfizer Pharmaceuticals Limited

8:15-8:50AM Registration for representatives and guests

8:00AM Innovation show open to the public all day

9:00AM Keynote Speeches
Topic: Anti-tumor monoclonal antibody drug discovery research and clinical diagnostic techniques

10 : 2 0AM Topics: Anti-immune diseases monoclonal antibody drug R&D, clinical diagnosis and treatment

10:40 AM Tea break/communication

11: 2 0AM Panel discussion: P rospects of monoclonal antibody therapy to tumor and antibody humanization ’s technology innovation

Antibody drugs’ big market prospect and the current existing technology problems have brought out a new technology revolution for antibody drugs. Engineering cell lines’ adaptability to the environment and large-scale cultivation of engineering cell lines have become the main bottlenecks of the antibody large-scale preparation and industrial development. How to innovate technologically in the humanization of antibody ？ What is the prospect of monoclonal antibody therapy on cancer? And how will Chinese antibody industry seek the effective method adaptable to the drug R&D environment?

Panelists:

Professor Zhinan Chen, Academician of Chinese Academy of Engineering ; Director of Cell Engineering Research Center , The Fourth Military Medical University
Leader of the group of experts of the National 863 Program Vaccines and antibody engineering major projects
Professor Yajun Guo, Director of People’s Liberation Army Second Military Medical University Cancer Institute ; Director of National Engineering Research Center of Antibody-based drugs
Mr. Qimin Zhan, Vice-President of Chinese Academy of Medical Sciences, Director of National Laboratory of Molecular Oncology
Mr. Jian Ding, Academician of Chinese Academy of Engineering, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
Mr. Li Yan, Deputy Director of R & D department of clinical anticancer drugs, Merck
Richard Robertson PhD, Senior Vice-president of Pre-clinical and drug development, Bristol-Myers Squibb
David Nicholson PhD, Senior Vice-president of International Drug Development, Schering-Plough
Vincent G. Brichard PhD, Vice-president of Immune Therapy Department, GlaxoSmithKline Biologicals, Belgium
Mr. Xinyuan Liu, Academician of Shanghai Academy of biochemical and cell, Chinese Academy of Sciences

12:30AM Buffet lunch

On the afternoon of Apr.23rd (Friday) u Seminar: The International conference for New Vaccine R&D and Clinical Diagnosis Technology

13:30PM Subject report
Topic: Infectious diseases, vaccine R & D and clinical diagnostics

15:10PM Tea break / Communication

15:25PM Topic: H1N1 influenza vaccine development and prevention, control, diagnosis and treatment
16:25PM Panel discussion: Under the framework of global R & D, new vaccines technological innovation and innovative cooperation with Asia

Case analysis, The changes for Traditional vaccine technologies migrate to the new vaccine technology; How to apply genetic engineering technology, improve traditional vaccine and solve the R&D problems of new vaccine, Face the global AIDS, influenza, hepatitis C, dengue fever, and other major diseases, the new vaccine research and create a key technical innovation, the infectious disease prevention in Asian countries , control, public health and the new vaccine technology trends? How Chinese vaccine developments effectively integrate into the international industrial chain of R & D to break through in innovation and development? And also how the vaccine manufacturers optimize industrial chain and share with global innovative cooperation?

Panelists:
Natalie Garcon PhD , Biopharmaceutical R&D Vice president of GSK USA
Peter Khoury PhD , Global vaccine marketing vice president of Baxter USA
John D. Clemens PhD , International vaccines superintendent of WHO
Jeffrey B. Ulmer PhD, Global cooperation R&D director of Novartis Vaccines UK
Laurent Bertin PhD, Vice President of External R & D Innovation, Sanofi-Aventis
（ GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION ， GAVI Alliance ）
Yu-Mei Wen, professor of Chinese Academy of Engineering / Fudan University
John D. Clemens ， PhD , Director general of International Vaccine Institute
Kelly Lyn Warfield PhD, Vaccine R&D Vice president of Integrated
Yue-long Su, vice superintendent of CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION. / Director of Chinese National Influenza Center

17: 1 0PM Forum closing

Conference fees: Home: RMB 2980 per person ( RMB2680 for member ), Abroad: USD1490 per person

Advertisement in the journal: RMB4000 per edition (16K color page)

Exhibition ： The show area is 9 quare meters ( 3m * 3m ).Home: RMB8000, Abroad: USD2100

Contact us

Kelly Zhou
Add: 4F ,Offshore Oil Tower, No.583 Lingling Rd, Shanghai, P.R. China Post code ： 200030
Tel:+86- 021-34241885 34241896
Fax: 021-64389235
E-mail: secma@
Website ：
www.